FDA-approved nasal spray treatment for treatment-resistant depression, providing rapid relief under medical supervision with comprehensive support and monitoring.
Our Spravato Treatment program offers a breakthrough option for treatment-resistant depression. Under careful medical supervision, Spravato (esketamine) nasal spray can provide rapid relief from depressive symptoms when other treatments haven't been effective.
Individuals with treatment-resistant depression
People who haven't responded to traditional antidepressants
Those seeking rapid relief from severe depression
Individuals under psychiatric care for depression
People looking for alternative depression treatments
Rapid improvement in depressive symptoms
Enhanced mood stability
Better response to overall treatment
Improved daily functioning
Reduced suicidal thoughts
Comprehensive assessment of depression history and treatment eligibility
Thorough health evaluation to ensure safe treatment
Education about the treatment process and expectations
Monitored Spravato treatment in a controlled setting
Observation period to ensure patient safety and comfort
Regular assessment of treatment response and benefits
Development of ongoing treatment schedule and support
Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression, used in conjunction with an oral antidepressant under medical supervision.
Treatment typically begins with twice-weekly sessions for 4 weeks, followed by once-weekly sessions for 4 weeks, then maintenance treatment based on individual response.
Spravato is specifically for adults with treatment-resistant depression who haven't responded to at least two different antidepressants. A thorough evaluation will determine if it's appropriate for you.
